Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial

Department of Public Health, San Antonio Metropolitan Health District, San Antonio, Texas, USA.
PEDIATRICS (Impact Factor: 5.3). 02/2009; 123(1):301-12. DOI: 10.1542/peds.2007-3317
Source: PubMed

ABSTRACT Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV; IPOL], and Haemophilus influenzae type b [Hib] vaccine [ActHIB]), when administered to infants and toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth (preschool) DTaP(5) dose.
In this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of DTaP(5) coadministered with IPV and Hib vaccines or 1 lot of DTaP(5)-IPV-Hib combination vaccine. Subsequently, 849 of these study participants were given a fourth dose of DTaP(5) and Hib vaccines or a fourth dose of DTaP(5)-IPV-Hib at 1 to 16 months of age. Safety was monitored throughout the study, and blood specimens were obtained to assess antibody responses.
DTaP(5)-IPV-Hib elicited similar or fewer solicited injection-site and systemic reactions as compared with the separate administration of US-licensed DTaP(5), IPV, and Hib vaccines. Seroresponse and seroprotection rates elicited by DTaP(5)-IPV-Hib were noninferior to US-licensed equivalent vaccines after the infant series and after the fourth dose. Children immunized with DTaP(5)-IPV-Hib had higher antibody geometric mean concentrations to pertussis toxoid and filamentous hemagglutinin; children immunized with the separate vaccines had higher responses to pertactin. Hib antibody responses to Hib polysaccharide were nearly identical in the DTaP(5)-IPV-Hib and separate-vaccine groups. Persistence of antibodies to the fifth (preschool) dose was also similar between groups.
DTaP(5)-IPV-Hib combination vaccine was shown to be immunogenic and well tolerated. No clinically important differences in the safety or immunologic profiles were noted for DTaP(5)-IPV-Hib versus the separately administered, US-licensed equivalent vaccines. DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines.


Available from: Fernando R Noriega, Jun 15, 2015
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pertussis and Bordetella pertussis infections since 1906 are reviewed with an attempt to address facts, myths, and misconceptions. Clinical pertussis is a noninflammatory illness which occurs without fever or productive cough, and its hallmark is the distinctive paroxysmal cough. Because of its significant mortality and morbidity, whole-cell vaccines were developed in the 1930s, and the universal use of these vaccines decreased the incidence of reported pertussis 157-fold by 1970. Because of real and perceived reactions to diphtheria and tetanus toxoids and whole cell pertussis vaccine (DTwP) vaccines, diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) vaccines were developed and put into universal use in the USA in 1997. Pertussis has two epidemiologies; one is reported pertussis and the other is B. pertussis illness. The study of these two epidemiologies indicate that reported pertussis is just the tip of the iceberg and B. pertussis cough illnesses occur in all age groups and they are very common; also, asymptomatic infection is more common than symptomatic infection. DTaP vaccines are less reactogenic than DTwP vaccines, but their effectiveness is less. B. pertussis infection is caused by many protein antigens, but illness due to this organism is caused by just two factors, pertussis toxin (PT) and a “cough toxin” which, as yet, has not been discovered. The present “resurgence of pertussis” is mainly due to greater awareness and the use of PCR for diagnosis. There are also many other factors which have contributed to the “resurgence.” New vaccines are clearly needed; with our present vaccines (DTaP and adolescent and adult formulated tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap)), if used correctly, severe pertussis and deaths in infants can be prevented.
    06/2015; 2(2). DOI:10.1007/s40471-015-0041-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: Penta-valent-vaccine is a combination vaccine administered in a 3-dose schedule, offers protection against diphtheria, tetanus, pertussis (DPT), hepatitis B and Haemophilus influenza type B (Hib. The vaccine is widely recommended by WHO and GAVI as a substitute for prevailing vaccination practices against the above mentioned diseases and viruses. The vaccine has met with both positive and negative responses, which leads to uncertainties about the vaccine's safety. The pros and cons of the vaccine is to be evaluated carefully before the same is added to routine immunization schedule.
    Human Vaccines & Immunotherapeutics 05/2014; 10(7). DOI:10.4161/hv.28785 · 3.64 Impact Factor
  • PEDIATRICS 04/2012; 129(5):968-70. DOI:10.1542/peds.2011-2594 · 5.30 Impact Factor